NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

You don't know Merck has the monopoly? I believe it is because of the monopoly not the shortage that LP decided to find the replacement. Merck has PD1 inhibitor, TLR4 agonist, TLR7/8 agonist from Eikon, and other 20 new growth drivers either complementary to or synergistic with DCVax. I don't think LP likes Merck has too much leverage. That's why having the replacement of BCG is essential. You haven't answered my question: Is Decoy20 a good replacement of BCG?

Yorkville has investment in the company developing Decoy20. In the meantime, Yorkville also has investment in $NWBO. Is it coincidental? I really don't think so.

You would agree that Yorkville investment in $NWBO is a long short, would you not? How many shares does Yorkville own by now? 20m or 30m?

Call me delusional. I can smell the generational wealth!!!

https://fintel.io/so/us/indp/ya-global-master-spv

YA II PN, Ltd. ownership in INDP / Indaptus Therapeutics, Inc.
2025-02-18 - YA II PN, Ltd. has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,410,916 shares of Indaptus Therapeutics, Inc. (US:INDP). This represents 9.99 percent ownership of the company.

On November 14, 2025 the Company entered into a $5 million convertible Promissory Note financing (the “Note”) with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”). The Company plans to use the financing proceeds for some of the construction and equipment costs for the first Grade C manufacturing suite in its Sawston, UK facility, as well as for ongoing Company operations.

The term of the Note is 12 months. No payments are due until maturity. The Note carries an Original Issue Discount of five percent but no interest. The Note includes customary default provisions. During the term of the Note, it is convertible at the option of the holder, at a small discount to the then prevailing market price. The amounts of such conversions are limited to approximately one fifth (1/5) of the overall Note amount in any given calendar month unless the conversion price is above $0.29.

As previously disclosed, on December 19, 2024, the Company entered into a Standby Equity Purchase Agreement (“SEPA”) with YA II PN, LTD (“Yorkville”). Upon entry into the SEPA, the Company issued Yorkville a $5.0 million convertible promissory note for net proceeds of $4.7 million after a 7% original issue discount (the “December Yorkville Note”). During the six months ended June 30, 2025, the Company issued 17.4 million shares of common stock to convert $4.1 million of the December Yorkville Note. As of June 30, 2025, the December Yorkville Note has remaining principal balance of $0.9 million.

On June 30, 2025, the Company and Yorkville entered into a supplemental agreement (the “SEPA Supplemental Agreement”) to increase the amount of convertible promissory notes allowed to be issued by $3.0 million (the “Additional Pre-Paid Advance Amount”). On June 30, 2025, the Company issued Yorkville a $3.0 million convertible promissory note for net proceeds of $2.9 million after a 5% original issue discount (the “June Yorkville Note”). The June Yorkville Note does not bear interest and matures on June 30, 2026. The June Yorkville Note is convertible into the Company’s common Stock at a conversion price equal to the lower of (i) $0.2932 per share (the “Fixed Price”), or (ii) a price per share equal to 95% of the lowest daily VWAP during the 5 consecutive trading days immediately prior to the conversion date (the “Variable Price”). The amounts of such conversions are limited to $0.8 million in any given calendar month unless the conversion price is above $0.2932 per share.

The Company elected the FVO to fair value the June Yorkville Note on the issuance date and will subsequently remeasure at the end of each reporting period. The estimated fair value of the June Yorkville Note on the issuance date was approximate $3.8 million. The Company recognized a loss of $0.8 million upon the issuance of the June Yorkville Note, which was calculated at the difference between the principal amount and the fair value of the note. As of June 30, 2025, the fair value of the remaining December Yorkville Note and June Yorkville Note was $4.8 million, which was included in Convertible notes at fair value, net of current portion on the consolidated balance sheets.

https://www.onclive.com/view/persistent-bcg-shortages-lead-to-hard-choices-in-bladder-cancer

Merck does not blame the shortage on regulations that limit what it can charge many payers for BCG. Brewer said the company seeks to profit from its recent innovations rather than exploit its accidental status as the monopoly provider of a treatment that’s nearly 100 years old, and he affirmed Merck’s commitment to ending shortages.

Overcoming Merck's BCG Monopoly: ImmunityBio Joins Forces with SII
https://www.echemi.com/cms/1867333.html

As rival Merck monopolizes BCG supply, ImmunityBio taps Serum Institute for new combo's manufacturing
https://www.fiercepharma.com/manufacturing/rival-merck-monopolizes-bcg-supply-immuntybio-taps-serum-institute-new-combos